Therapies targeting specific molecular processes, in particular kinases, are major strategies to treat cancer. Genomic features are commonly used as biomarkers for drug sensitivity, but our ability to stratify patients based on these features is still limited. As response to kinase inhibitors is a dynamic process affecting largely signal transduction, we investigated the association between cell-specific dynamic signaling pathways and drug sensitivity. We measured 14 phosphoproteins under 43 different perturbed conditions (combination of 5 stimuli and 7 inhibitors) for 14 colorectal cancer cell-lines, and built cell-line-specific dynamic logic models of the underlying signaling network. Model parameters, representing pathway dynamics, were used as features to predict sensitivity to a panel of 27 drugs. This analysis revealed associations between cell-specific signaling pathways and drug sensitivity for 14 of the drugs, 9 of which have no genomic biomarker. Following one of these associations, we validated a drug combination predicted to overcome resistance to MEK inhibitors by co-blockade of GSK3. These results underscore the value of perturbation-based studies to find biomarkers and combination therapies complementing those based on a static genomic characterization.
[Main Text:] Introduction
Patient response to anticancer therapies is extremely variable and understanding the reasons for this variability is a major challenge in cancer research. One approach to address this problem is to identify biomarkers which correlate with therapy response.
However, except for a few examples, no efficient biomarkers are available (1) . The problem of finding biomarkers has become even more important with the advent of targeted cancer therapies that are designed to affect specific molecular changes in cancer cells which drive the cancer, and which provide a larger number of treatment options. However, biomarkers that can be used to stratify patients for targeted drugs also remain largely elusive (2) .
The most common approaches for patient stratification are currently based on genomic biomarkers, typically consisting of either expression or mutation of specific genes. The popularity of those biomarkers has been favoured by the advancements of sequencing technology and their subsequent decrease in cost, and, for some drugs, they have shown strong potential (3) (4) (5) . However, for many other cases no efficient genomic markers for patient stratification exist, and for those where markers exist, they have rather low power due to the complex nature of cancer. Furthermore, their actual clinical significance for precision oncology is questionable (1).
Many modern drugs target signaling molecules, and elicit a response of the signaling network. Therefore, investigating the functioning of signaling pathways can provide new insights into these mechanisms and may help to unveil new therapeutic strategies and biomarkers (6, 7) . Understanding how drugs affect the signaling network as a whole is particularly important as signaling dynamic differs not only between tumors of different tissue, but also between tumors of the same tissue. For instance, for colon and liver cancer cell-lines, the dynamics of signaling networks have been shown to differ strongly between different cells of the same tissue of origin (8) (9) (10) .
Furthermore, models parameterized and experimentally calibrated using a specific cell-line have been used to define pathway dynamic biomarkers of therapeutic outcome, such as drug sensitivity (11) or patient survival (12) , based on model simulations in breast cancer and neuroblastoma, respectively.
The understanding of mechanisms of cellular response (network structure and dynamic behaviour), can be also useful to tackle the development of compensatory signaling mechanisms of drug resistance (13) , which is a recurrent problem for targeted therapy and is challenging to predict based only on genomic information.
Signal transduction results from the integration of complex dynamic networks which can be modulated by mutations in oncogenes or tumor suppressors. The complex wiring confers a robustness to the cells that helps them to escape most single-agenttargeted treatments. Based on this idea, modeling of signaling pathways has been recently used to suggest combinatorial targeted therapies to effectively block multiple molecular pathways (8, 14, 15) : by integration of prior pathway knowledge with experimental observations cell-line-specific models were built, which could be used to simulate and thus prioritize possible combinatorial perturbation experiments.
In this paper, we investigate to what extent dynamic interactions between different signaling pathways play a role in characterizing the specific cellular responses to drugs and suggesting targeted combinatorial therapies. Furthermore we were interested to assess how these dynamic features fare against static genomic traits as markers of drug response. We do so by characterizing cell-type-specific models for a panel of 14 different colorectal cancer (CRC) cell-lines that are integrated with a large-scale drug screening (16) . We found associations with model parameters for 14 of the 27 drugs targeting our pathways of interests, for 9 of which there were no genomic biomarkers. These associations was used to define pathway dynamic biomarkers and interesting combinatorial therapies.
Results
To identify biomarkers of drug response from dynamic logic models, we proceed as follows (Fig. 1) . First, cell-line-specific models were built for 14 colorectal cancer (CRC) cell-lines. Each model is a set of logic ordinary differential equations (17) based on a prior knowledge network (PKN) manually curated from literature ( Fig.   1A ) that is refined using CellNOpt (18) based on experimental data. Second, sensitivity data for our 14 cell-lines in response to drugs targeting nodes in the PKN or first neighbours were retrieved from the Genomics of Drug Sensitivity in Cancer (GDSC) panel (16) (Fig. 1B) . Third, we investigated correlations between model parameters and drug response using Elastic Net (19) to select strong associations (Fig. 1C) . All steps will be detailed in the following sections.
Strategy for model optimization: a toy example
Our starting point is a prior knowledge network (PKN), which is generic in the sense that it contains information about different cell types and is hence not clear about how many of the contained interactions are functional in a given cell type. To identify cell-specific functional components, the PKN was trained as a logic model to cellspecific data. The dynamics of the system were modelled using a formalism based on logic ordinary differential equations (ODEs) (17) , where a set of ODEs (one for each species in the model) was derived from the logic structure using a continuous update function (see Materials and Methods). Each species (i.e. node in the network) was characterized by a parameter τ i (with i=1,...,N where N is the number of species in the model) representing its life-time (τ=0 meaning that the node is not functional), and each regulatory interaction was defined by a sigmoid function, where a parameter k i,j characterizes the strength of the regulation of species i dependent on species j (k i,j =0 meaning no regulation).
In order to be able to deal with large-scale networks including the effect of multiple signaling pathways and their cross-talks, building on (18, 20) we developed a new calibration approach that uses L1 regularization to prune the network by inducing sparsity thus reducing the size of the model. The approach can be illustrated using the in silico model in Fig. 2A , where the PKN includes 9 nodes and 14 edges. A subnetwork (10 edges shown in black in Fig. 2A ) was used to generate in silico data for 2 readouts (nodes shown in blue in Fig. 2A) , consisting of 9 perturbations, which are some of the possible combinations of 2 stimuli (green nodes) and 2 inhibitors (targeting red nodes). In silico data were generated for 10 random sets of parameters (one example shown in Fig. 2B ) and were then used to optimize the model by minimizing Q LS (τ,k), which is defined as the sum of the squared difference between model predictions and true (in silico) values. Although the fit of the optimized models to the data was perfect, parameters could not be well estimated due to model redundancy and low identifiability. In order to improve parameter estimates, we redefined the objective function Q introducing a L1 regularization term on the parameters τ i to help the model remove the unconnected nodes (e.g. P4 and P5 in Fig. 2A ). This was achieved by penalising the complexity of the model as:
where (1) The term λ τ controls the importance of the regularization term. We plotted the effect of increasing values of λ τ for the in silico model on P and Q LS (Fig. 2C) , and on the accuracy of parameter estimates (as a sum of the square of the difference between estimated and true parameters) (Fig. 2D) . As expected, for increasing values of λ τ , Q LS tends to increase (worse fit to the data) while P tends to decrease (sparser model). Good values of λ τ are those on the elbow of the L-shaped curve in Fig. 2C , corresponding to the best compromise between good fit and sparse model.
Interestingly, these values (especially λ τ =0.001 which represents the most conservative choice in terms of regularization) also correspond to the best accuracy in estimating the parameters in Fig. 2D . Looking at the estimated parameters we could verify that for λ τ =0.001 the parameters τ P4 and τ P5 were indeed set to zero thanks to the regularization term in the objective function.
Generation of cell-line-specific models
The previously illustrated approach was applied to systematically characterize how To characterize the signaling pathways we started from a comprehensive general prior-knowledge network (PKN) derived from the literature and public databases using OmniPath (21) . The PKN was first compressed to reduce model complexity without affecting logic consistency as described in ( 
Heterogeneity of the cell-line specific models
We further analysed the heterogeneity of the estimated parameters (Fig. 3) nor at the level of pathway models (Fig. 4C) . to characterize each cell-line with a specific signaling model.
Association of model parameters with drug response data
We next investigated if the previously defined highly heterogenous model parameters can be associated with the efficacy of drugs. We reasoned that since the mode of action of multiple drugs involves affecting the functioning of the pathways we were modeling, their functional status should affect the efficacy of the drugs.
Since all our 14 colorectal cancer cell-lines are part of the Genomics of Drug Sensitivity in Cancer (GDSC) panel (16), we could make use of the drug sensitivity data included in this comprehensive dataset in response to a large panel of drugs. In particular, in order to focus on biologically relevant associations, we selected only those drugs targeting nodes in our network (PKN) or first neighbours, i.e. targets that directly regulate a node in the PKN based on Omnipath (21), which is a curated ensemble of multiple pathway resources. We additionally excluded drugs showing a low variability in the response across our 14 cell-lines (less than three sensitive and three resistant cell-lines based on the classification used in (16)) and those for which sensitivity data were missing for more than three of our 14 cell-lines. For the remaining 27 drugs, we investigated the association with our model parameters using cross-validated Elastic Net (details in Materials and Methods), using IC50s
(half maximal inhibitory concentration) as a measure of drug sensitivity. We found a total of 146 robust associations (out of the 1242 possible ones), with 14 of our 27 drugs being explained by at least one model parameter. Top 50 associations are shown in Fig. 5A and all associations are shown in fig. S2 . Resulting associations were then compared with those between drugs and genomic alterations (functional mutations and copy number alterations) acting on PKN nodes or first neighbor.
Genetic biomarkers were identified using ANOVA as described in (16) (without correction for multiple hypothesis testing due to too large number of comparisons, see fig. S3 ) resulting in associations for 12 of our 27 drugs, five of which also showed associations with model parameters (corresponding genetic biomarkers are reported for the drugs in Fig. 5A ).
Interpretation and validation of the dynamic biomarkers
We then focused on the 9 drugs whose efficacy was not significantly associated with mutations or copy number alterations but instead with pathway biomarkers, to explore how our approach provides insights in otherwise unexplained drug efficacy.
Top associations are illustrated in 
Discussion
While it is broadly accepted that alterations in the functionality of signaling pathways largely determine the efficacy of kinase inhibitors used in the clinic, a complete understanding of their relationship is lacking. In this study we investigate this relationship and we show that the dynamic of signaling pathways can determine the efficacy of targeted drug treatments, in particular in cases where genomic data cannot. Additionally, we show that this information can be used to guide combinatorial therapies.
Our means towards this end were cell-specific mechanistic models of signal transduction for 14 colorectal cancer cell-lines trained with dedicated phosphoproteomic data upon perturbations. We built our models based on differential equations to capture the continuous aspects of signal strength and timedynamics, but using a logic formalism that allowed for straightforward interpretability of the model parameters in terms of life-time of each species in the network and strength of the regulatory interactions. We could then study how these model parameters, which determine the dynamic behaviour of the pathway, are related with the global cellular sensitivity to cancer drugs. We found some strong correlations between model parameters and drug sensitivity, such as between GSK3 life-time and MEK inhibitors, that suggest that the functionality of pathway interactions is indeed related to the efficacy of the drugs. anticancer effect in recent studies on cancer cell-lines (29, 30) and its potential interaction with MEK-ERK pathway has also been suggested in this context (30, 31) but, as far as we know, no proven synergistic effect had previously been reported.
Our findings underscore the value of studying signaling pathways dynamic to better understand tumor phenotypes and to exploit this knowledge to suggest new therapeutic strategies (32) . Such an approach is fundamentally different from the currently common characterization of various 'omics' layers at the basal level and it can be exploited to prevent the dynamic adaptation mechanisms underlying drug resistance (14) . Accordingly, we were able to find various pathway dynamic biomarkers for drugs with no genetic biomarkers. Hence, we believe that a perturbation-based strategy, even if restricted to fewer genetic backgrounds and only monitoring selected proteins, can provide a complementary strategy for biomarker discovery in cancer and beyond.
Materials and methods

Definition of logic ordinary differential equations
The logic ordinary differential equation formalism (17) is based on ordinary differential equations derived from logic models using a continuous update function for each species , which can assume continuous values . The differential equation for species is defined as follow:
Where is the life-time of species . means that the node is disconnected by the rest of the network and higher values of represent faster response, that can be interpreted as more functional species. are the N regulators of and each regulation is defined by a transfer function with parameters and :
Where parameters were fixed to 3 and parameters were optimized (constrained between 0 and 1 included). As shown in fig. S4 , means that the transfer function is equal to 0 for any value of the regulator j and can be interpreted 5Z-7-Oxozeanol (5µM). Concentrations were selected to inhibit target while minimizing off-target activity. We further used the following ligands: EGF (25ng/ml), HGF (50ng/ml), IGF1 (10ng/ml), TGFb (5ng/ml) and TNFa (10ng/ml). After treatment and incubation, lysates were collected and analyzed with the Bio Plex Protein Array system (Bio Rad, Hercules, CA) as described earlier (8) and 100 with 100 corresponding to the negative control (cells with no treatment) and 0 to the positive control (cells treated with Staurosporine 2µM). Same DMSO volume was maintained for all experiments (negative and positive controls, single drug and drug combination). Cell number was measured after 3 days of constant drug exposure using CellTiter-Glo reagent as described by the manufacturer (Promega).
Data preprocessing
For each cell-line, data were processed separately for each of the 14 measured
phosphoproteins. The value of the control (unperturbed condition) was estimated as the median value of the 4 replicates (to decrease the risk of bias) and log2 fold changes with respect to the control were then computed for each of the 42 perturbed conditions. As required by our logic formalism, data were then linearly scaled between 0 and 1, with 0.5 corresponding to the basal (control) condition.
Model optimization
The optimization procedure applied to each cell-line is the following:
1. L1 regularization was applied to parameters τ i to remove unconnected nodes, as described in Equation 1, for five increasing values of λ τ (λ τ =0, 0.01, 0.1, 1, 10). To increase the chances to obtain good solutions, 10 independent runs of the optimization were run in parallel. The best value for λ τ was selected (λ τ =0.1) which provided the optimal balance between fitting precision and network size as described in the example, using the L-shaped curves ( fig.   S5 ). 
Statistical Analysis
ANOVA was used to define genomic markers of drug sensitivity using the GDSC tools (https://pypi.python.org/pypi/gdsctools/0.2.0). Microsatellite instability was used as covariate and threshold on minimum size of the positive and negative population for each feature set to 3. The threshold for significance of the p-value was set to 0.05, but no correction for multiple hypothesis testing was applied.
Kruskal-Wallis rank sum test (which is a one-way analysis of variance on ranks) was used to test if estimated parameters (from bootstrap) derive from the same distribution for all 14 cell-lines (null hypothesis rejected if different for at least one group). Effect size w was computed as where χ 2 is the statistics from the test and N is the number of observations. Effect size >0.5 is considered as large effect. P-values were Bonferroni corrected and threshold was set to 0.05. Wilcoxon rank sum test was then used for post hoc pairwise test on parameters passing the Kruskal-Wallis rank sum test, using as effect size , where Z is the statistics from the test and N is the number of observations. Effect size >0.5 is considered as large effect. P-values were Bonferroni corrected and threshold was set to 0.05. Rank type test were preferred over parametric tests because they are highly robust against non-normality.
Supplementary Materials
Fig. S1. Extended version of the prior-knowledge network (PKN). Corresponding model parameter associations for each drug are shown in the PKN using the same colour code to mark edges corresponding to regulator parameters k ij (edge from i to j) and nodes border for corresponding life-time parameters τ i (node i). 
